A Phase II Study of Sunitinib (NSC 736511, IND 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients

Trial Profile

A Phase II Study of Sunitinib (NSC 736511, IND 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2015

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Anaplastic astrocytoma; Ependymoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Apr 2013 New source identified and integrated (Memorial Sloan-Kettering Cancer Center; 13-026).
    • 04 Mar 2013 Planned End Date changed from 1 Oct 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top